What Medications Can Cause Raynaud’s Syndrome?

Dozens of medications across at least twelve drug classes can trigger Raynaud’s phenomenon, the condition where small blood vessels in your fingers or toes spasm in response to cold or stress, turning them white or blue and causing numbness or pain. A comprehensive review identified chemotherapy drugs like cisplatin and bleomycin as carrying the highest risk, followed by beta-blockers and a surprisingly wide range of other medications, from ADHD stimulants to newer migraine drugs.¹ The mechanisms vary just as widely, including ramped-up sympathetic nerve activity, direct damage to blood vessel linings, and interference with the body’s natural vasodilators.²

Chemotherapy Drugs Carry the Highest Known Risk

Among all medications linked to Raynaud’s, the combination chemotherapy regimens used for testicular cancer stand out. In a study of 60 men treated with vinblastine and bleomycin, with or without cisplatin, about 37 percent developed Raynaud’s phenomenon. The risk was notably higher when cisplatin was part of the regimen, with roughly 41 percent of those patients affected compared to about 21 percent of those on vinblastine and bleomycin alone.³ Hand imaging in affected patients showed diffuse arterial narrowing and abrupt vessel cutoffs, suggesting that these drugs cause genuine structural changes in the blood vessels rather than just temporary spasms.

Bleomycin appears to damage the endothelial lining of small arteries directly, while cisplatin adds to the problem through a separate toxic mechanism. The result is that Raynaud’s from chemotherapy tends to be a delayed side effect, sometimes appearing weeks or months after treatment, and it can persist long after the drugs are stopped. This distinguishes it from most other drug-induced Raynaud’s, which tends to be reversible.

Newer targeted cancer therapies are raising similar concerns. Tyrosine kinase inhibitors, used in a growing number of cancers, have been flagged as possible triggers through a mechanism that remains unclear.¹ Since these drugs are prescribed for long-term use, even a modest vascular side effect becomes clinically relevant over time.

The Beta-Blocker Question Is More Complicated Than You Think

If you search for medications that cause Raynaud’s, beta-blockers almost always top the list. Drug labels, FDA guidelines, and European prescribing recommendations consistently warn about peripheral vasoconstriction. Yet the clinical evidence behind this warning is surprisingly thin. Multiple controlled studies found no measurable worsening of finger blood flow or increase in vasospastic attacks from beta-blockers compared to placebo.

One study tested propranolol and metoprolol against placebo in 16 patients who already had Raynaud’s phenomenon. Neither drug produced significant changes in finger blood flow, finger skin pressure, or the frequency of attacks. The authors concluded that Raynaud’s phenomenon is not a contraindication to beta-blocker use in normotensive patients.⁴ Another study comparing propranolol, metoprolol, and pindolol found no adverse effect of any type of beta-blocker on baseline finger skin perfusion or recovery after a cold challenge, in either Raynaud’s patients or people with hypertension.⁵

A systematic review and network meta-analysis went further, concluding that beta-blockers have variable tendencies to enhance peripheral vasoconstriction and that the effect is not simply a matter of whether the drug is cardioselective. The authors argued that their findings challenge both FDA and European recommendations, and suggested that beta-blockers with intrinsic sympathomimetic activity could be safely used in patients with peripheral vascular disease.⁶

That said, individual case reports do exist. One published case described a patient who developed Raynaud’s symptoms after starting metoprolol succinate, and those symptoms resolved within a week of stopping the drug and had not recurred over eighteen months of follow-up.⁷ So the disconnect is real: the average patient on a beta-blocker does not appear to be at meaningful risk, but susceptible individuals can develop clear and reproducible symptoms. If you are prescribed a beta-blocker and notice new color changes or coldness in your fingers, it is worth mentioning to your prescriber, but the blanket fear surrounding this drug class is probably overstated.

ADHD Stimulants

Stimulant medications for ADHD have drawn increasing attention as a cause of Raynaud’s. Methylphenidate, amphetamine, dextroamphetamine, lisdexamfetamine, and less commonly atomoxetine have all been implicated.⁸ These drugs work by boosting levels of norepinephrine and dopamine in the brain, but the same increase in catecholamines at the periphery can clamp down on small blood vessels.⁹

A large pharmacovigilance analysis using the FDA’s adverse event database found that lisdexamfetamine and methylphenidate had some of the strongest statistical signals for Raynaud’s among all nervous system drugs, with reporting odds ratios of roughly 25 and 8, respectively.² Those numbers reflect how disproportionately often these drugs appear alongside Raynaud’s reports compared to other medications, though they do not tell you the absolute risk for any individual patient.

Most cases are mild. A systematic review of ADHD medication-associated Raynaud’s found that the majority of cases resolved within weeks once the drug was stopped, the dose was reduced, or the patient was switched to a different medication. Assessment of 28 cases suggested a probable or definite causative role of the ADHD drug in more than half.⁸ However, the picture is not always benign. Severe outcomes have been documented, including digital ulceration, gangrene, and in rare cases amputation or the need for surgical revascularization.

A scoping review reported that irreversible tissue losses, including digital autoamputation and limb-threatening ischemia, have been attributed to treatment with central nervous system stimulants.¹⁰ These extreme cases likely involve patients who already had underlying vascular vulnerability, but they underline why persistent cold-sensitivity or color changes in the fingers while on a stimulant deserve clinical attention.

Children and Adolescents on Stimulants

The ADHD-Raynaud’s connection matters especially for younger patients. The majority of studies identified in the scoping review involved children or adolescents, which makes sense given that ADHD diagnoses and stimulant prescriptions are most common in school-age populations.¹⁰ A child may not articulate finger color changes or numbness clearly, and a parent might attribute cold hands to the weather without considering the medication as a factor. If a child on a stimulant consistently complains about painful or discolored fingertips, particularly in cooler conditions, bringing it up with their pediatrician is a reasonable step.

Migraine Medications

Several drug classes used for migraines can provoke Raynaud’s through different mechanisms. Ergotamine, one of the oldest migraine treatments, is a potent vasoconstrictor and has long been associated with peripheral ischemia. Triptans like sumatriptan work by activating serotonin receptors on cranial blood vessels to relieve migraine pain, but that serotonin-mediated constriction can affect peripheral vessels as well.

A newer class of migraine preventives has joined the list. CGRP inhibitors, including drugs like erenumab and fremanezumab, block calcitonin gene-related peptide from binding to its receptor. CGRP is one of the body’s most potent vasodilators, so blocking it raises peripheral vascular tone, especially when you are already cold or stressed. The FDA adverse event analysis found that erenumab and fremanezumab both showed positive disproportionality signals for Raynaud’s.² Since CGRP inhibitors are relatively new and their use is growing rapidly, this is an area where real-world data is still accumulating. If you already experience cold-sensitive fingers and are considering a CGRP inhibitor for migraines, the overlap is worth discussing with your neurologist.

Interferon Therapies

Interferons, used historically for conditions ranging from multiple sclerosis to certain blood cancers, have been linked to Raynaud’s in case reports that describe sometimes dramatic vascular damage. One report documented a woman with multiple sclerosis who developed severe Raynaud’s, a mottled skin pattern called livedo reticularis, and digital necrosis just two weeks after starting interferon-beta. Her symptoms improved after stopping the drug and starting anticoagulation with immunosuppressive treatment.¹¹

In another case, a woman treated with interferon for chronic myelogenous leukemia developed severe finger tissue damage after 49 months of therapy, with arteriography confirming digital artery occlusions.¹² While interferon use has declined for some of these indications as newer treatments have become available, interferons remain part of the treatment landscape for certain conditions, and the vascular risk is worth knowing about for patients on long-term therapy.

Cocaine and Other Vasoconstrictors

Cocaine is a powerful sympathomimetic, and its ability to trigger intense peripheral vasoconstriction makes it an underappreciated cause of Raynaud’s. Case reports have described patients presenting with painful, discolored digits whose urine drug screens revealed cocaine use, sometimes alongside amphetamines or synthetic cannabinoids.¹³ In one case, a 37-year-old man developed ischemic finger necrosis and new-onset Raynaud’s associated with cocaine abuse.¹⁴

This is relevant because patients may not disclose recreational drug use to their doctors, and clinicians evaluating new Raynaud’s symptoms might not think to ask about it. The vasoconstriction from cocaine is intense and repeatable, and digital necrosis from chronic cocaine use is a recognized surgical complication. Over-the-counter sympathomimetic decongestants like pseudoephedrine share a milder version of the same mechanism. They work by constricting blood vessels in the nasal passages, but that constriction is not perfectly localized and can affect peripheral circulation in susceptible individuals.

Estrogen, Oral Contraceptives, and Vascular Sensitivity

Raynaud’s phenomenon is significantly more common in premenopausal women than in age-matched men. Estrogen appears to play a role by amplifying the expression and function of a specific adrenergic receptor subtype that mediates cooling-induced vasoconstriction.¹⁵ This means the hormonal environment itself is a risk factor, but it also raises questions about medications that supply exogenous estrogen.

Studies comparing finger skin perfusion across groups with different hormonal profiles have found that women using oral contraceptives and premenopausal women show more pronounced and prolonged cold-induced vasoconstriction compared to men. Recovery after a cold challenge was also slower in women on oral contraceptives than in males.¹⁶ This does not mean oral contraceptives “cause” Raynaud’s in the same direct way that stimulants or chemotherapy drugs do, but they appear to shift your vascular physiology in a direction that makes cold-induced vasospasm more likely. For women who already have borderline Raynaud’s symptoms, starting estrogen-containing contraception could tip the balance.

How These Drugs Trigger Vasospasm

There is no single mechanism behind drug-induced Raynaud’s. A review identified at least four broad pathways by which medications cause peripheral vasospasm:¹

Sympathetic overdrive: Stimulants and cocaine flood the body with norepinephrine, which activates receptors on small artery smooth muscle cells that trigger constriction.
Endothelial damage: Chemotherapy drugs like bleomycin and cisplatin injure the inner lining of blood vessels, permanently reducing their ability to dilate.
Neurotoxicity: Some drugs damage the peripheral nerves that regulate vascular tone, disrupting the delicate balance between constriction and dilation.
Reduced red blood cell flexibility: Certain agents make red blood cells stiffer, impairing their flow through the smallest capillaries and worsening ischemia during a vasospastic episode.

Some drugs hit more than one pathway. Cisplatin, for example, is directly toxic to endothelial cells and may also affect nerve function, which helps explain why it carries such high risk. CGRP inhibitors work through yet another route entirely, blocking a vasodilatory peptide rather than actively promoting constriction, but the net result for the peripheral vasculature is similar.

When Drug-Induced Raynaud’s Resolves

One of the most reassuring aspects of drug-induced Raynaud’s is that it tends to be reversible when the culprit medication is identified and removed. In the systematic review of ADHD medications, most cases resolved within weeks of discontinuation, dose reduction, or switching to an alternative drug.⁸ The metoprolol case report noted symptom resolution within one week of stopping the beta-blocker, with no recurrence over a year and a half.⁷

The important exception is chemotherapy-induced Raynaud’s, which can persist because the underlying damage to blood vessel walls may be structural and permanent rather than purely functional. Interferon-induced cases also sometimes involve arterial occlusions visible on imaging, suggesting lasting vascular injury rather than simple spasm. The general rule: drugs that work through nerve stimulation or receptor blockade tend to produce reversible Raynaud’s, while drugs that physically damage blood vessels can produce lasting symptoms. This is why early recognition matters so much. The longer a vasoconstrictive drug continues while vascular symptoms are present, the greater the chance of tissue damage that will not fully reverse.

Practical Steps if You Suspect a Medication Is the Cause

If you develop new Raynaud’s symptoms, especially within weeks of starting or increasing a medication, the timing alone is a useful clue. Drug-induced Raynaud’s typically tracks with the medication timeline in a way that primary (idiopathic) Raynaud’s does not. Your doctor can help work through the differential by checking whether the onset lines up with the drug, whether symptoms improve when the drug is paused, and whether there are signs of an underlying autoimmune condition that might explain secondary Raynaud’s on its own.

Not every drug on this list needs to be avoided by every person with cold-sensitive fingers. As the beta-blocker evidence shows, a drug class widely labeled as dangerous for Raynaud’s may be well tolerated by most patients. Context matters: your underlying vascular health, other medications you take, environmental cold exposure, and whether you have a connective tissue disorder all influence whether a given drug will push you past the threshold. The practical approach is awareness rather than blanket avoidance. Know which of your medications have the potential to affect peripheral circulation, report new symptoms promptly, and work with your prescriber to weigh the benefits of the drug against the severity of the vascular side effect.

1
PubMed Central. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers
2
Scientific Reports. A comprehensive study on drug-related Raynaud’s phenomenon based on the FDA adverse event reporting system
3
PubMed. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer
4
PubMed. Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud’s phenomenon
5
PubMed. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud’s phenomenon and in hypertension
6
PubMed Central. Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis
7
CMAJ. Drug-induced Raynaud phenomenon following initiation of metoprolol succinate
8
PubMed. Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review
9
The Primary Care Companion for CNS Disorders. Rare Side Effects of Stimulants: Raynaud’s Phenomenon
10
Seminars in Arthritis and Rheumatism. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud’s phenomenon: A scoping review
11
PubMed. Severe Raynaud’s phenomenon associated with interferon-beta therapy for multiple sclerosis: case report
12
PubMed. Severe Raynaud’s syndrome associated with interferon therapy. A case history
13
PubMed Central. Cocaine-Induced Raynaud’s Phenomenon: A Case Report
14
PubMed. Cocaine-Induced raynaud’s phenomenon and ischaemic finger necrosis
15
PubMed Central. Cold responses and hormonal echoes: a comprehensive view of Raynaud’s vascular dysfunction
16
PubMed. Skin vascular reactivity in healthy subjects: influence of hormonal status